Abstract | Background: Methods: In this retrospective, observational cohort study, we analyzed the outcome of 55 patients with membranous nephropathy treated between 1990 and 2017 with a 6-month course of alternating steroids (months 1, 3, and 5) plus intravenous cyclophosphamide (single dose of 15 mg/kg on the first day of months 2, 4, and 6). Results: At 24 months, 39 (71%) patients achieved clinical response with complete remission observed in 23 patients (42%) and partial remission in 16 (29%). Median time to achieve partial and complete remission was 5.9 and 11.5 months, respectively. Absence of response was observed in 16 patients (29%), five of whom started chronic RRT after a median follow-up of 3.5 years. Clinical relapse occurred in nine of 33 (27%) patients at a median of 34 months after treatment discontinuation. Conclusions: Replacement of oral cyclophosphamide with a single intravenous pulse on months 2, 4, and 6 of the modified Ponticelli regimen can be an effective and safe alternative for treatment of membranous nephropathy. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/K360/2020_09_24_KID0002802020.mp3.
|
Authors | Leonella Luzardo, Gabriela Ottati, Jimena Cabrera, Hernando Trujillo, Mariela Garau, Carlota González Bedat, Ruben Coitiño, María H Aunchayna, José Santiago, Graciela Baldovinos, Ricardo Silvariño, Alejandro Ferreiro, Francisco González-Martínez, Liliana Gadola, Oscar Noboa, Hena Caorsi |
Journal | Kidney360
(Kidney360)
Vol. 1
Issue 9
Pg. 943-949
(09 24 2020)
ISSN: 2641-7650 [Electronic] United States |
PMID | 35369556
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2020 by the American Society of Nephrology. |
Chemical References |
- Immunosuppressive Agents
- Cyclophosphamide
|
Topics |
- Cyclophosphamide
(adverse effects)
- Glomerulonephritis, Membranous
(drug therapy)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Remission Induction
- Retrospective Studies
|